School of Population Health (X.X., L.Z., A.E.S.), University of New South Wales Sydney, Kensington, Australia.
The George Institute for Global Health (X.X., B.N., A.E.S.), University of New South Wales Sydney, Kensington, Australia.
Hypertension. 2024 Mar;81(3):400-414. doi: 10.1161/HYPERTENSIONAHA.123.21343. Epub 2024 Jan 29.
Excess dietary sodium intake and insufficient dietary potassium intake are both well-established risk factors for hypertension. Despite some successful initiatives, efforts to control hypertension by improving dietary intake have largely failed because the changes required are mostly too hard to implement. Consistent recent data from randomized controlled trials show that potassium-enriched, sodium-reduced salt substitutes are an effective option for improving consumption levels and reducing blood pressure and the rates of cardiovascular events and deaths. Yet, salt substitutes are inconsistently recommended and rarely used. We sought to define the extent to which evidence about the likely benefits and harms of potassium-enriched salt substitutes has been incorporated into clinical management by systematically searching guidelines for the management of hypertension or chronic kidney disease. We found incomplete and inconsistent recommendations about the use of potassium-enriched salt substitutes in the 32 hypertension and 14 kidney guidelines that we reviewed. Discussion among the authors identified the possibility of updating clinical guidelines to provide consistent advice about the use of potassium-enriched salt for hypertension control. Draft wording was chosen to commence debate and progress consensus building: strong recommendation for patients with hypertension-potassium-enriched salt with a composition of 75% sodium chloride and 25% potassium chloride should be recommended to all patients with hypertension, unless they have advanced kidney disease, are using a potassium supplement, are using a potassium-sparing diuretic, or have another contraindication. We strongly encourage clinical guideline bodies to review their recommendations about the use of potassium-enriched salt substitutes at the earliest opportunity.
过量的膳食钠摄入和不足的膳食钾摄入都是高血压的明确危险因素。尽管采取了一些成功的举措,但通过改善饮食来控制高血压的努力基本上都失败了,因为所需的改变大多难以实施。最近来自随机对照试验的一致数据表明,富含钾、减少钠的盐替代品是改善摄入量、降低血压以及心血管事件和死亡发生率的有效选择。然而,盐替代品的推荐并不一致,也很少使用。我们试图通过系统地搜索高血压或慢性肾病管理指南,来确定关于富含钾盐替代品的可能益处和危害的证据在多大程度上被纳入临床管理。我们发现,在我们审查的 32 份高血压和 14 份肾脏指南中,关于使用富含钾盐替代品的建议不完整且不一致。作者之间的讨论确定了更新临床指南以提供关于使用富含钾盐控制高血压的一致建议的可能性。选择了起草措辞以开始辩论并推进共识建设:强烈建议所有高血压患者使用富含钾盐-氯化钠 75%和氯化钾 25%的配方,除非他们患有晚期肾病、正在使用钾补充剂、正在使用保钾利尿剂或有其他禁忌症。我们强烈鼓励临床指南制定机构尽早审查其关于使用富含钾盐替代品的建议。